{
  "drug_name": "orotic acid",
  "nbk_id": "NBK545275",
  "url": "https://www.ncbi.nlm.nih.gov/books/NBK545275/",
  "scraped_at": "2026-01-11T18:47:40",
  "sections": {
    "indications": "The mean corpuscular volume (MCV) is a critical measurement for identifying the underlying cause of anemia. MCV is a laboratory value that measures the average size and volume of red blood cells (RBCs), providing essential information in the diagnostic process for anemia. MCV is expressed as femtoliters (fL). To calculate the MCV, the percent hematocrit is divided by the erythrocyte count, and the result is multiplied by 10:\n\nMCV (in fL) = (Hematocrit %)/(RBC×10\n12\n/L)×10\n\nDescriptively, MCV is viewed as a footprint of the anemia, indicating the characteristics of RBCs. In conjunction with other parameters such as hemoglobin and hematocrit, MCV classifies anemia into 3 main categories—microcytic, normocytic, and macrocytic. MCV levels below, within, and above the normal range define microcytic, normocytic, and macrocytic anemia, respectively. Furthermore, MCV guides the red blood cell distribution width (RDW) calculation.",
    "mechanism": "Clinicians use MCV to definitively diagnose the type of anemia—microcytic, normocytic, and macrocytic. Microcytic anemia is characterized by erythrocytes smaller than normal and significantly smaller than leukocytes. On a complete blood count (CBC), the MCV measure is below 80 fL, whereas a normal MCV ranges between 80 and 100 fL. This type of anemia is commonly associated with chronic iron-deficiency anemia, sideroblastic anemia, and thalassemias, although the anemia can also occur in other conditions. Microcytic cells may exhibit a larger area of central pallor, particularly in the context of iron-deficiency anemia and anemia of chronic disease.\n\nMacrocytic anemia is characterized by an increased average RBC volume compared to normal levels, with an MCV measurement exceeding 100 fL on a CBC. Macrocytic anemia is further categorized into megaloblastic, characterized by impaired DNA synthesis, or non-megaloblastic, where DNA synthesis remains normal. Megaloblastic anemia is commonly caused by folate deficiencies (folic acid or vitamin B9), cobalamin/vitamin B12, or orotic aciduria. This autosomal recessive disorder hinders the conversion of orotic acid to uridine monophosphate. On the other hand, non-megaloblastic anemia can result from hepatic insufficiency, chronic alcoholism, or a rare congenital disease known as Diamond-Blackfan anemia.\n\nNormocytic anemia has a low hemoglobin and hematocrit range, but MCV is in the normal range of 80 to 100 fL. This type of anemia can be subclassified into hemolytic or non-hemolytic. Normocytic hemolytic anemia can occur intravascularly and extravascularly due to various underlying causes. Other laboratory values on the CBC further indicate the type of anemia, aiding in diagnosis. Non-hemolytic normocytic anemias may present in conditions such as early anemia of chronic disease, early iron-deficiency anemia, aplastic anemia, microangiopathic hemolytic anemias, and certain plasmodial infections.",
    "monitoring": "A CBC, which includes hemoglobin, hematocrit, and MCV measurements, is essential for determining the type of anemia. The specific diagnostic approach for microcytic anemia depends on the patient's presentation. For instance, if a menstruating woman presents with an MCV below 80 fL and exhibits symptoms such as menorrhagia, further investigations such as a Von Willebrand factor assay and thyroid panel may be necessary to ascertain the underlying cause related to menstrual history. On the contrary, in patients with microcytic anemia aged 50 or older, a colonoscopy is typically recommended to investigate whether the iron deficiency originates from colonic polyps or neoplasms. Additional diagnostic steps may include a urea breath test and an upper endoscopy to assess for\nHelicobacter pylori\n, especially if the patient reports symptoms suggestive of gastritis-type pain.\n\nWhen managing patients with anemia of chronic disease with an unknown cause, several diagnostic tests are necessary. These include assessments for rheumatoid factor, anti-double-stranded DNA antibodies, anti-neutrophil cytoplasmic antibodies, and anti-myeloperoxidase antibodies. In addition, a urine spot test should be conducted to evaluate renal function by measuring parameters such as glomerular filtration rate, creatinine, and blood urea nitrogen levels. Screening for HLA-B27 and rheumatologic antibodies is also crucial. Consideration may be given to malignancy screening using imaging modalities such as computed tomography (CT) scans or chest x-rays.\n\nA blood lead level test is the gold-standard diagnostic tool for suspected lead poisoning. However, a bone marrow biopsy is necessary if other causes of sideroblastic anemia are possible. Obtaining a detailed medical history is crucial in identifying the underlying etiology, potentially avoiding a bone marrow biopsy. Suspected β-thalassemia cases can be further evaluated through hemoglobin electrophoresis to determine the proportions of hemoglobin A versus A2. For α-thalassemia, genetic analysis offers superior diagnostic accuracy.\n\nPeripheral blood smear and urine analysis are essential for distinguishing between intravascular and extravascular hemolysis in normocytic anemia. The presence of schistocytes and hemoglobin in the urine suggests microangiopathic hemolytic anemia. However, despite suspected hemolysis, the absence of schistocytes in the peripheral blood smear and the absence of hemoglobin in the urine warrant further investigation. Detection of spherocytes in the peripheral blood smear prompts a direct Coombs test to differentiate autoimmune hemolytic anemia from splenic sequestration in hereditary spherocytosis, aiding diagnosis.\n\nRenal analysis demonstrates an inverse relationship between MCV and bone marrow density in patients on dialysis, observed with hemodialysis but not peritoneal dialysis. Reticulocyte mean corpuscular volume (MCVr), representing larger and younger cells, is typically elevated compared to mature RBCs. Monitoring MCVr can be instrumental in tracking recovery from various conditions, ranging from iron deficiency (microcytosis) to megaloblastic anemia, providing valuable clinical insights.\n\nIn cases of macrocytic anemia, obtaining a detailed history and performing a thorough physical examination are crucial for identifying potential causes, such as chronic alcoholism, liver failure, malabsorptive disorders, or dietary deficiencies, including veganism without vitamin supplementation. Notably, assessing vitamin B12 and folate levels is crucial, considering folate supplementation can mask underlying vitamin B12 deficiency. Suspected orotic aciduria necessitates urine analysis to detect orotic acid and ammonia levels. The ammonia test can differentiate a deficiency in ornithine transcarbamylase versus orotic aciduria. Due to the rarity of Diamond-Blackfan anemia, a detailed history, a thorough physical examination, and CBC are typically sufficient for diagnosis. However, due to associated predispositions, clinicians may opt for follow-up computed tomography (CT) scans to screen for potential malignancies.\n[19]\n[26]\n[27]",
    "administration": "Microcytic Anemia\n\nTreatment for microcytic anemia due to iron-deficiency anemia typically involves iron supplementation for premenopausal women. In some cases, women may also receive treatment with oral contraceptive pills to regulate menstrual cycles and reduce menstrual flow or levothyroxine if the cause is secondary to hypothyroidism.\n\nMacrocytic Anemia\n\nTreatment for macrocytic anemia varies depending on the underlying causes. For vitamin B12 and folate deficiencies, supplementation with folate and vitamin B12 is the standard therapeutic approach. Individuals who consume alcohol are advised to discontinue alcohol consumption and are often supplemented with folate. Patients diagnosed with orotic aciduria typically require supplementation with uridine monophosphate synthase to bypass the deficient enzyme and restore normal function.\n[28]\n\nNormocytic Anemia\n\nTreatment for patients with paroxysmal nocturnal hemoglobinuria typically involves the use of eculizumab, which can effectively reduce hemolysis and prevent complications such as portal hypertension resulting from venous thromboses.\n[29]\nBlood transfusions may be necessary in severe anemia to restore hemoglobin levels. Patients with bone marrow failure may undergo hematopoietic stem cell transplantation as a potential treatment option. For patients with macroangiopathic hemolytic anemia secondary to conditions such as prosthetic heart valves or aortic stenosis, surgical interventions such as valve repair or replacement may be considered. Patients with intravascular hemolysis due to malaria or babesiosis require treatment with appropriate anti-malarial or babesiosis medications to manage the underlying infection effectively.\n\nMicroangiopathic hemolytic anemia can arise from thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, systemic lupus erythematosus, hypertensive emergency, and HELLP syndrome. Patients with thrombotic thrombocytopenic purpura are treated with plasmapheresis and corticosteroids. Patients with hemolytic uremic syndrome are treated with plasmapheresis, which is similar to thrombotic thrombocytopenic purpura. Patients with systemic lupus erythematosus are treated with prednisone to decrease flares, hydroxychloroquine, mycophenolate mofetil, and tumor necrosis factor (TNF)-α inhibitors. Patients with HELLP syndrome are treated with antihypertensives such as labetalol or hydralazine, magnesium sulfate to prevent convulsions, corticosteroids to further develop the baby's lung development before delivery, and blood transfusion if required due to thrombocytopenia.\n\nTreatment for hereditary spherocytosis includes folate supplementation, blood transfusions if hemoglobin falls below 7 g/dL, and erythropoietin administration for infants up to 9 months old. Vaccination against encapsulated bacteria is recommended as a final step before splenectomy. Autoimmune hemolytic anemia is initially managed with glucocorticoids and then with cytotoxic drugs such as rituximab if the condition is refractory.\n[30]\nAplastic anemia treatment involves identifying and removing any causative agents if possible. Hematopoietic stem cell transplants are commonly used for the management.\n[31]\n\nTreatment for anemia of chronic disease commonly involves anti-inflammatories, corticosteroids, and TNF-α inhibitors unless malignancy is the underlying cause, in which case the malignancy requires a standard treatment protocol. Lead poisoning is managed with chelation therapy using dimercaprol, EDTA, and succimer for children. Copper deficiency requires copper supplementation. Patients taking isoniazid with vitamin B6 deficiency should receive vitamin B6 supplementation and discontinue isoniazid. Immediate cessation of chronic alcohol intake is necessary. Thalassemias are managed differently depending on severity; most cases do not require medication or transfusions, but therapy for β-thalassemia may include chronic blood transfusions.\n\nOther types of thalassemia typically remain asymptomatic and do not necessitate treatment. Iron supplementation is contraindicated, especially in patients receiving chronic transfusions, due to concerns about acquired hemochromatosis. If\nH pylori\nis suspected, a urea breath test is necessary. An upper endoscopy can also be performed for biopsy and to assess severity, particularly because this bacterium is associated with premalignant conditions.",
    "adverse_effects": "The lack of treatment and increased mortality are common complications for anemias with varying MCV. Patients with iron-deficiency anemia without supplementation can develop high-output heart failure. Lead poisoning can also be fatal without chelation therapy and removal of the causal agent. Untreated diseases such as systemic lupus erythematosus can lead to renal insufficiency, which is the most common cause of death in these patients. Patients with β-thalassemia major are prone to complications from treatment, such as acquired hemochromatosis. Without chronic chelation therapy, these patients are at risk of death from iron intoxication and restrictive pericarditis due to iron deposition in the pericardium.\n\nFolate deficiency can lead to complications in pregnant patients, causing neural tube defects in the developing fetus. Vitamin B12 deficiency can result in subacute combined degeneration of the nervous system. Unfortunately, without appropriate supplementation, conditions such as orotic aciduria and Diamond-Blackfan anemia can be fatal. Patients with hepatic insufficiency or cirrhosis face a spectrum of complications, including hyperammonemia, ascites, portal hypertension, cardiomegaly, esophageal varices with a risk of rupture and hemorrhage, internal hemorrhoids, hepatorenal syndrome, and hepatic encephalopathy. Chronic alcoholism can also contribute to these complications due to alcoholic cirrhosis, along with the development of Wernicke-Korsakoff syndrome resulting from thiamine deficiency. Normocytic anemia can lead to various complications such as hemoglobinuria, hematuria, syncope, petechial rashes, high fevers, and death. Timely and effective treatment is crucial in mitigating these potential complications and improving patient outcomes."
  }
}